PRDX5 and gastric cancer: Clinically used inhibitor of thioredoxin reductase, auranofin, displayed synergistic lethality with GSH inhibitor piperlongumine in gastric cancer (GC) suggesting that combined inhibition of different antioxidant systems is more effective in killing cancer cells than abrogation of the activity of single ones.